PharmaCyte Biotech Inc PMCB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PMCB is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $2.03
- Day Range
- $1.98–1.98
- 52-Week Range
- $1.91–2.82
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $16.74 Mil
- Volume/Avg
- 1,735 / 17,580
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 187.08%
Company Profile
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
- Website
- https://pharmacyte.com
Comparables
Valuation
|
Metric
|
PMCB
|
MRSN
|
CELC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.54 | 9.18 | 4.31 |
Price/Sales | — | 6.56 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PMCB
|
MRSN
|
CELC
|
|---|---|---|---|
Quick Ratio | 8.12 | 3.43 | 10.64 |
Current Ratio | 8.16 | 3.51 | 11.23 |
Interest Coverage | — | −34.91 | −13.89 |
Quick Ratio
PMCB
MRSN
CELC
Profitability
|
Metric
|
PMCB
|
MRSN
|
CELC
|
|---|---|---|---|
Return on Assets (Normalized) | −0.61% | −41.22% | −40.23% |
Return on Equity (Normalized) | −0.89% | −196.75% | −56.35% |
Return on Invested Capital (Normalized) | −6.07% | −129.55% | −44.81% |
Return on Assets
PMCB
MRSN
CELC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Ksjsngjb | Ytq | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Nvxcfptr | Jfftmd | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ytyqblkv | Fvgtlg | $118.7 Bil | |||
| Moderna Inc
MRNA
| Zjqngjwv | Xjhkh | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Fwswxlrqq | Ghhppm | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Stqdwcwnc | Xrgq | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Qfmzqscqz | Kgb | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qlhyfwy | Hldvr | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Jmlqfdh | Vctsq | $15.0 Bil | |||
| Incyte Corp
INCY
| Jydcxwl | Wskyvh | $13.5 Bil |